drugset / Trial / NCT05708924
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Phase 1
Terminated
1 enrolled
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
To determine the maximum tolerated dose (MTD) of FT538 monotherapy when administered via intraperitoneal (IP) catheter and in combination with intravenous (IV) enoblituzumab in patients with recurrent ovarian, fallopian tube, and primary peritoneal cancer.
Timeline
- Start
- 2023-04-28
- Primary completion
- 2024-08-06
- Completion
- 2024-08-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enoblituzumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | FT538 | Cell therapy | 5e+07 cells | Other |
| Subject | FT538 | Cell therapy | 1e+08 cells | Other |
| Subject | FT538 | Cell therapy | 3e+08 cells | Other |
| Subject | FT538 | Cell therapy | 1e+09 cells | Other |
| Subject | FT538 | Cell therapy | 1.5e+09 cells | Other |